1 Correction to: Clinical Drug Investigation (2019) 39:805–819 https://doi.org/10.1007/s40261-019-00826-0
The original version of this article unfortunately contained some mistakes. The corrected details are provided below:
Page 805:The title of the article, which previously read:
“Glucagon-Like Peptide-1 Receptor Analogues in Type 2 Diabetes: Their Use and Differential Features”
should read:
“Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features”
Running header, which previously read:
“Glucagon-Like Peptide-1 Receptor Analogues in Type 2 Diabetes”
should read:
“Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes”
Page 805, Abstract:The beginning of the first sentence, which previously read:
“Glucagon-like peptide-1 receptor analogues/agonists”
should read:
“Glucagon-like peptide-1 receptor agonists”
Page 805, Section 1, para 2, end of the second sentence, which previously read:
“thereby providing the rationale for developing GLP-1 receptor analogues/agonists (GLP-1RAs) to treat T2D [3].”
Should read:
“thereby providing the rationale for developing GLP-1 receptor agonists (GLP-1RAs) to treat T2D [3].”
Page 811, Section 4, para 2, end of the first sentence, which previously read:
“some other glucose-lowering drugs (most frequently semaglutide vs sitagliptin or insulin glargine [28–32]) [Table 3]”
Should read:
“some other glucose-lowering drugs (most frequently semaglutide vs sitagliptin or insulin glargine [28–32]) [Table 3].”
Page 817, first column, last para, first sentence, which previously read:
“GLP-1RAs must be administered subcutaneously, which is disadvantage relative to the convenient oral administration of most other classes of glucose-lowering drugs.”
Should read:
“GLP-1RAs must be administered subcutaneously, which is a disadvantage relative to the convenient oral administration of most other classes of glucose-lowering drugs.”
Captions of Table 1 (page 807), Table 2 (page 808), Table 3 (page 812), Table 4 (page 814), Table 5 (page 815) and Table 6 (page 816): The part of the table caption, which previously read:
“glucagon-like peptide-1 receptor analogues”
should read:
“glucagon-like peptide-1 receptor agonists”
The following section was inadvertently omitted:
Acknowledgements The author thanks Prof. John Wilding, Obesity & Endocrinology Research, Institute of Ageing & Chronic Disease, University of Liverpool, Liverpool, UK for his assistance in preparing this review.
The original article has been corrected.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lyseng-Williamson, K.A. Correction to: Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features. Clin Drug Investig 39, 915–916 (2019). https://doi.org/10.1007/s40261-019-00839-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40261-019-00839-9